As for the biological mechanism, the isolation of CTCs is based on the antigen–antibody combination in which the common markers include EpCAM as a cancer stem cell marker, and HER2 and PSA as the targets for breast and prostate cancer, respectively [90,91]. The gene discussed is KLK3; the disease is prostate carcinoma.